Pablo Ortiz Betes
Technik-/Wissenschafts-/F&E-Leiter bei One Way Liver SL
Profil
Pablo Ortiz Betes is currently a Professor at Universitat Pompeu Fabra and the Chief Scientific Officer at One Way Liver SL.
Previously, he worked as a Director at ProRetina Therapeutics SL and as the General Manager at Digna Biotech SL.
He holds a doctorate degree from Universidad Autónoma de Madrid, which he obtained in 1990 and 1978.
Aktive Positionen von Pablo Ortiz Betes
| Unternehmen | Position | Beginn |
|---|---|---|
One Way Liver SL
 One Way Liver SL Miscellaneous Commercial ServicesCommercial Services One Way Liver SL designs and develops diagnostic solutions for liver conditions. It designs and develops of non-invasive diagnostic solutions for hepatic conditions, such as fatty liver disease and non-alcoholic steatohepatitis. The firm also provides research and clinical testing services to clients in the pharmaceutical and biomedical product industries. The company was founded by José Maria Mato de la Paz in 2002 and is headquartered in Derio, Spain. | Technik-/Wissenschafts-/F&E-Leiter | - |
| Universitat Pompeu Fabra | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Pablo Ortiz Betes
| Unternehmen | Position | Ende |
|---|---|---|
Digna Biotech SL
 Digna Biotech SL BiotechnologyHealth Technology Digna Biotech is a holding company which provides biomedical dsicovery, research, development, and clinical testing services to clients in the pharmaceutical sector. Its pipeline consists of products for the treatment of sclerodermia, keratosis, multiple sclerosis, corneal ulcers, porphyria, and acute liver failure. The company was founded on February 23, 2003 and is headquartered in Pamplona, Spain. | Vorstandsvorsitzender | - |
ProRetina Therapeutics SL
 ProRetina Therapeutics SL BiotechnologyHealth Technology ProRetina Therapeutics SL develops drugs for the treatment of retinal conditions. Its pipeline includes PRO-001 used for the treatment of retinitis pigmentosa and PRO-015 is a gene vector that codes the human proinsulin gene indicated for Retinitis Pigmentosa. The company was founded by Stuart Medina in 2007 and is headquartered in Noain, Spain. | Direktor/Vorstandsmitglied | - |
Ausbildung von Pablo Ortiz Betes
| Universidad Autónoma de Madrid | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
Digna Biotech SL
Digna Biotech SL BiotechnologyHealth Technology Digna Biotech is a holding company which provides biomedical dsicovery, research, development, and clinical testing services to clients in the pharmaceutical sector. Its pipeline consists of products for the treatment of sclerodermia, keratosis, multiple sclerosis, corneal ulcers, porphyria, and acute liver failure. The company was founded on February 23, 2003 and is headquartered in Pamplona, Spain. | Health Technology |
One Way Liver SL
One Way Liver SL Miscellaneous Commercial ServicesCommercial Services One Way Liver SL designs and develops diagnostic solutions for liver conditions. It designs and develops of non-invasive diagnostic solutions for hepatic conditions, such as fatty liver disease and non-alcoholic steatohepatitis. The firm also provides research and clinical testing services to clients in the pharmaceutical and biomedical product industries. The company was founded by José Maria Mato de la Paz in 2002 and is headquartered in Derio, Spain. | Commercial Services |
ProRetina Therapeutics SL
ProRetina Therapeutics SL BiotechnologyHealth Technology ProRetina Therapeutics SL develops drugs for the treatment of retinal conditions. Its pipeline includes PRO-001 used for the treatment of retinitis pigmentosa and PRO-015 is a gene vector that codes the human proinsulin gene indicated for Retinitis Pigmentosa. The company was founded by Stuart Medina in 2007 and is headquartered in Noain, Spain. | Health Technology |
